Showing results (191-200 of 274) with videos related to

Sort By:
Pageof 28
Nature Communications|November 25, 2024
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2018
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerYelena Y Janjigian, Johanna Bendell, Emiliano Calvo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032Neal Ready, Anna F Farago, Filippo de Braud, et al.
ESMO Open|August 21, 2020
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trialsAndrew X Zhu, Ryan D Nipp, Richard S Finn, et al.
BMC Cancer|April 26, 2023
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centreDavid K Lau, Caroline Fong, Faten Arouri, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC StudyFiona Turkes, Annette Bryant, Ruwaida Begum, et al.
Journal of Gastroenterology and Hepatology|September 30, 2017
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOWKei Muro, Jae Yong Cho, Gyorgy Bodoky, et al.
Cancers|May 27, 2026
Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre ExperienceKai Tai Derek Yeung, Simon Gomberg, William Hodgson, et al.
Pageof 28